All lobbying filings

TIBER CREEK GROUP

Lobbying for ALNYLAM PHARMACEUTICALS, INC. · Biopharmaceuticals.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · Massachusetts · House · Senate · $60,000.00 income · posted Apr 18, 2025

Official filing document

Bills named in this filing 1

HR 1672
Maintaining Investments in New Innovation Act

Lobbying activity 1

Medicare/Medicaid

Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Medicare Part D and Part B Pricing Reform; Issues related to home infusion under Medicare FFS; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.